Weiss Ratings Reaffirms “Sell (D-)” Rating for ALT5 Sigma (NASDAQ:ALTS)

ALT5 Sigma (NASDAQ:ALTS)‘s stock had its “sell (d-)” rating reiterated by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen cut ALT5 Sigma from a “hold” rating to a “strong sell” rating in a report on Saturday, August 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

ALT5 Sigma Stock Up 3.6%

NASDAQ:ALTS opened at $2.89 on Wednesday. The stock has a 50 day simple moving average of $5.01 and a 200 day simple moving average of $6.26. The company has a debt-to-equity ratio of 1.45, a current ratio of 0.88 and a quick ratio of 0.88. ALT5 Sigma has a 1-year low of $1.65 and a 1-year high of $10.95.

Insiders Place Their Bets

In related news, Director David C. Danziger acquired 10,000 shares of the company’s stock in a transaction on Thursday, August 14th. The stock was purchased at an average cost of $7.30 per share, with a total value of $73,000.00. Following the acquisition, the director directly owned 20,000 shares of the company’s stock, valued at approximately $146,000. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.65% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ALT5 Sigma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALTS. Evernest Financial Advisors LLC acquired a new position in ALT5 Sigma in the 2nd quarter valued at $87,000. Geode Capital Management LLC raised its holdings in ALT5 Sigma by 27.6% in the 2nd quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock valued at $1,412,000 after acquiring an additional 42,157 shares in the last quarter. Jane Street Group LLC acquired a new position in ALT5 Sigma in the 2nd quarter valued at $380,000. Finally, Bridgeway Capital Management LLC raised its holdings in ALT5 Sigma by 9.4% in the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after acquiring an additional 1,661 shares in the last quarter. 6.27% of the stock is owned by institutional investors and hedge funds.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.